PATH | VRL
Menu

The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group A Meningococcal Conjugate Vaccine for Africa

This supplement issue of Clinical Infectious Diseases contains 29 articles that together cover the steps taken for the development, introduction, and evaluation of MenAfriVac®, a meningococcal A conjugate vaccine developed specifically for Africa through a partnership with the World Health Organization and PATH. MenAfriVac® has drastically reduced the cases of meningitis A disease in the African “meningitis belt,” but scientists are now warning that unless countries within the belt incorporate the vaccine into routine immunization schedules for infants, there is a risk that the disease could rebound.

Author: LaForce FM, Borrow R, Preziosi M-P, eds.

Published: 2015

» Visit web page (English)

(Located at cid.oxfordjournals.org)

Citation: LaForce FM, Borrow R, Preziosi M-P, eds. The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group A Meningococcal Conjugate Vaccine for Africa. Clinical Infectious Diseases. 2015;61(Suppl 5):S387-S600.

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Introduction and service delivery, Disease burden and surveillance, Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa